Advancing Alzheimer’s Research with Probucol

The PIA Study aims to test Probucol, a potential new treatment for Alzheimer’s disease. Previously used to treat cardiovascular disease and stroke, Probucol shows promise in supporting memory performance in Alzheimer’s patients safely.

Study Objectives

This trial seeks to determine whether Probucol can support memory and thinking skills in participants with mild dementia due to Alzheimer’s disease. Specifically, it aims to provide evidence that Probucol treatment may slow the decline of cognitive abilities and functional state.

Clinical Trial Overview

The clinical trial spans 104 weeks (2 years) of daily oral dosing of either Probucol or a placebo.

Total Study Duration

Up to 112 weeks (2 years and 8 weeks), including screening and follow-up.

Screening Period

Up to 56 days before receiving the study drug to determine suitability.

Treatment Groups

Participants will receive either Probucol or a placebo, determined by a computer-generated schedule. This double-blind design ensures neither participants nor researchers know the assigned treatment, though this information can be accessed in emergencies.

Visits and Calls

Participants will attend 14 clinic visits and receive 7 phone calls over the study period.

No Overnight Stays

There are no overnight confinement periods required.

Visit Details

Visits will last between 1 to 3 hours, depending on the scheduled activities, which may include:

• Medical and disease history review
• Alzheimer’s disease assessment
• Physical and neurological examinations
• Vital sign measurements
• Blood samples
• ECG
• PET scan
• MRI

Participation Requirements

A partner, spouse, or carer is required to:

• Attend at least one screening visit
• Complete a questionnaire
• Be available via phone or in-person to provide necessary information for the study duration.